CHRISTINE RIEGER: Open Payments
NPI 1861921926 · ESCONDIDO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,669 in 118 payments from 11 companies in 2025. Trend: 2023 $1,814 · 2024 $1,690 · 2025 $2,669
Food & beverage: $2,558Education: $111
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $491 |
| Vanda Pharmaceuticals Inc. | 14 | $447 |
| Neurocrine BioSciences, Inc. | 7 | $327 |
| Teva Pharmaceuticals USA, Inc. | 11 | $295 |
| Alkermes, Inc. | 15 | $285 |
| Janssen Pharmaceuticals, Inc | 13 | $263 |
| Otsuka America Pharmaceutical, Inc. | 11 | $220 |
| E.R. Squibb & Sons, L.L.C. | 11 | $158 |
| Lundbeck LLC | 4 | $85 |
| ABBVIE INC. | 3 | $65 |
Products named: CAPLYTA, HETLIOZ, INGREZZA, ARISTADA, REXULTI, INVEGA SUSTENNA, COBENFY, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
